← Back to screener

MADRIGAL PHARMACEUTICALS, INC. MDGL

Rank #2478 · Nasdaq · $9.9B market cap
Audited by PricewaterhouseCoopers LLP, no going-concern flag in the latest filing.
Score
14.7
P/E
-26.6
P/B
50.27
ROE
-189.3%
Op. Margin
–%
Debt Ratio
146%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆
Poor

P/E -26.6x, P/B 50.27x. Ranks in the top 84% of the universe.

Profitability ★☆☆☆☆
Poor

ROE -189.3%. Ranks in the top 97% of the universe.

Safety ★★☆☆☆
Average

Debt ratio 146%. Ranks in the top 52% of the universe.

Growth –
No data

Not enough historical filings to compute year-over-year growth yet.

Safety is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2011–$0.1B–$-0.1B–-52
2012–$-0.0B–$0.0B–111
2013–$-0.0B–$0.0B–119
2014$0.0B$-0.1B–$0.0B-41456.5312
2015–$-0.1B–$0.1B–47
2016–$-0.0B–$-0.0B–-117
2017–$-0.0B$-0.0B$-0.0B–-10
2018–$-0.0B$-0.0B$-0.0B–-21
2019$0.0B$-0.0B$-0.0B$0.0B–23
2020$0.0B$-0.0B$-0.0B$0.2B–14
2021$0.0B$-0.1B$-0.1B$0.5B–10
2022$0.0B$-0.2B$-0.2B$0.4B–19
2023$0.0B$-0.2B$-0.2B$0.2B–69
2024$0.0B$-0.3B$-0.3B$0.2B–120
2025$0.0B$-0.4B$-0.4B$0.2B–146

← See the full screener